标题
Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1)
作者
关键词
-
出版物
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume -, Issue -, Pages -
出版商
The Endocrine Society
发表日期
2022-07-28
DOI
10.1210/clinem/dgac433
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Burosumab treatment for fibrous dysplasia
- (2021) Anne Gladding et al. BONE
- Burosumab for the Treatment of Tumor‐Induced Osteomalacia
- (2020) Suzanne M Jan de Beur et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
- (2019) Michael P Whyte et al. Lancet Diabetes & Endocrinology
- FGF23 and its role in X-linked hypophosphatemia-related morbidity
- (2019) Signe Sparre Beck-Nielsen et al. Orphanet Journal of Rare Diseases
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
- (2019) Erik A Imel et al. LANCET
- Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
- (2019) Dieter Haffner et al. Nature Reviews Nephrology
- Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
- (2019) Anthony A. Portale et al. CALCIFIED TISSUE INTERNATIONAL
- FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis
- (2019) Ineke Böckmann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
- (2019) Karl L Insogna et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion
- (2019) Patricia P. Centeno et al. Nature Communications
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
- (2018) Karl L Insogna et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Burosumab Therapy in Children with X-Linked Hypophosphatemia
- (2018) Thomas O. Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- FGF23 Actions on Target Tissues—With and Without Klotho
- (2018) Beatrice Richter et al. Frontiers in Endocrinology
- Fibroblast Growth Factor 23 to Alpha-Klotho Index Correlates with Systemic Sclerosis Activity: A Proposal for Novel Disease Activity Marker
- (2018) Przemyslaw Kotyla et al. Journal of Clinical Medicine
- FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction
- (2017) Edward R. Smith et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice
- (2016) Shoji Ichikawa et al. ENDOCRINOLOGY
- Hypophosphatemia promotes lower rates of muscle ATP synthesis
- (2016) Dominik H. Pesta et al. FASEB JOURNAL
- Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease
- (2016) Saurav Singh et al. KIDNEY INTERNATIONAL
- FGF23 promotes myocardial fibrosis in mice through activation of β-catenin
- (2016) Huixin Hao et al. Oncotarget
- Minimally Invasive Surgical Management of Thoracic Ossification of the Ligamentum Flavum Associated with X-linked Hypophosphatemia
- (2016) Alexander R. Riccio et al. World Neurosurgery
- Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy
- (2015) Alexander Grabner et al. Cell Metabolism
- Enthesis fibrocartilage cells originate from a population of Hedgehog-responsive cells modulated by the loading environment
- (2014) A. G. Schwartz et al. DEVELOPMENT
- Surgical Treatment for Ossification of the Posterior Longitudinal Ligament in the Cervical Spine
- (2014) Howard S. An et al. JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
- Mineralizing Enthesopathy Is a Common Feature of Renal Phosphate-Wasting Disorders Attributed to FGF23 and Is Exacerbated by Standard Therapy in Hyp Mice
- (2012) Andrew C. Karaplis et al. ENDOCRINOLOGY
- Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation
- (2010) Outi Mäkitie et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations
- (2010) Erik A. Imel et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hereditary disorders of renal phosphate wasting
- (2010) Amir S. Alizadeh Naderi et al. Nature Reviews Nephrology
- FGF23 and the parathyroid glands
- (2010) Justin Silver et al. PEDIATRIC NEPHROLOGY
- Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice
- (2009) Guoying Liang et al. CALCIFIED TISSUE INTERNATIONAL
- Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets
- (2008) Emily G. Farrow et al. BONE
- Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
- (2008) U. S. Alon et al. Clinical Journal of the American Society of Nephrology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started